Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report published on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Trading Up 1.2 %

NASDAQ TENX opened at $3.49 on Thursday. The business’s 50-day moving average price is $3.73 and its two-hundred day moving average price is $3.61. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. As a group, sell-side analysts anticipate that Tenax Therapeutics will post -6.68 earnings per share for the current year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.